

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

ADOPTION OF RESTRICTED SHARE AWARD SCHEME

ADOPTION OF RESTRICTED SHARE AWARD SCHEME

The Board is pleased to announce that on 23 August 2021, the Company adopted the Scheme to, among other things, better retain and attract talents. The Scheme will initially be valid and effective for a period of ten (10) years commencing on the Effective Date.

Pursuant to the Scheme: (a) for Selected Participants other than US Participants, the Restricted Shares will be satisfied by (i) existing Shares to be acquired by the Trustee on the market, and/or (ii) new Shares to be allotted and issued to the Trustee by the Company under the general or specific mandate sought from the shareholders of the Company in its general meeting; and (b) for US Participants, the Restricted Shares will be satisfied by (i) authorized and unissued Shares, (ii) treasury shares (subject to Applicable Laws), (iii) Shares purchased on the open market, and/or (iv) at the discretion of the Board, ADRs (if any).

The total number of the Restricted Shares underlying all grants made pursuant to the Scheme and the 2019 Scheme shall not exceed ten per cent. (10%) of the issued share capital of the Company as at the adoption date of the 2019 Scheme.

The Scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules. No shareholders' approval is required to adopt the Scheme.

ADOPTION OF RESTRICTED SHARE AWARD SCHEME

The Board is pleased to announce that on 23 August 2021, the Company has adopted the Scheme to, among other things, better retain and attract talents.

Pursuant to the Scheme: (a) for Selected Participants other than US Participants, the Restricted Shares will be satisfied by (i) existing Shares to be acquired by the Trustee on the market, and/or (ii) new Shares to be allotted and issued to the Trustee by the Company under the general or specific mandate sought from the shareholders of the Company in its general meeting; and (b) for US Participants, the Restricted Shares will be satisfied by (i) authorized and unissued Shares, (ii) treasury shares (subject to Applicable Laws), (iii) Shares purchased on the open market, and/or (iv) at the discretion of the Board, ADRs (if any).

SUMMARY OF THE SCHEME

1. Purposes of the Scheme

The purposes of the Scheme are to (i) provide the Selected Participants with the opportunity to acquire proprietary interests in the Company; (ii) encourage the Selected Participants to work towards enhancing the value of the Company and its Shares or the benefit of the Company and its Shareholders as a whole; and (iii) provide the Company with a flexible means of either retaining, incentivizing, rewarding, remunerating, compensating and/or providing benefits to the Selected Participants.

2. Administration of the Scheme

The Scheme shall be subject to the administration of the Board and the Trustee in accordance with the terms of the Scheme and the Trust Deed. Unless otherwise specified herein, the decision of the Board and the Trustee regarding the administration and operation of the Scheme shall be final and binding on all parties.

The Board has the power to administer the Scheme, including the power to construe and interpret the Rules of the Scheme, and the terms of the Award granted under the Scheme. The Board may delegate the authority to administer the Scheme to a committee of the Board or other person(s) as deemed appropriate at the sole discretion of the Board. The Board or its delegate(s) may also appoint one or more independent third party contractors to assist in the administration of the Scheme as they may think fit. If there is such delegation of authority to a committee of the Board, the references to “the Board” shall be construed as references to such committee of the Board to the effect that such committee of the Board may administer the Scheme as appropriate.

3. Grant of Award

The Board may, at its sole discretion, determine which Eligible Participant(s) shall be entitled to receive grants of Restricted Shares under the Scheme, together with the number of Shares to which each Selected Participants shall be entitled, and make the relevant grant of Restricted Shares to the Selected Participant under the Scheme subject to such conditions as the Board may deem appropriate at its discretion.

Any proposed grant of the Restricted Shares under the Scheme to any connected person in relation to the Company or any of its subsidiaries must be approved by the independent non-executive directors of the Company (except where such connected person is an independent non-executive director of the Company, in which case such director shall abstain from such approval process) and in accordance with the requirements under the Listing Rules.

4. Restrictions on Grant

No grant of Restricted Shares shall be made to any Selected Participant under the Scheme where any Director and/or such Selected Participant is in possession of unpublished inside information in relation to the Company or any of its subsidiaries or where dealings in Shares have been suspended or dealings in Shares by any Director are prohibited under any code or requirement of the Listing Rules or any applicable legal or regulatory requirement from time to time or where such grant of the Restricted Shares would result in a breach of the Scheme Limit (as defined below).

5. Maximum Number of Shares to be Granted

The total number of the Restricted Shares underlying all grants made pursuant to the Scheme and the 2019 Scheme shall not exceed in total ten per cent. (10%) (i.e. 183,721,269 Shares) of the Company's issued share capital as at the adoption date of the 2019 Scheme (the "**Scheme Limit**"), provided that no account shall be taken into the calculation of the Scheme Limit of any Shares where the right to acquire such Shares has been cancelled, lapsed or forfeited in accordance with the Scheme.

6. Satisfaction of Awards

For Selected Participants other than US Participants, the Company shall (i) issue and allot Shares to the Trustee under the general mandates granted or to be granted by the Shareholders at the general meetings from time to time, and/or (ii) transfer to the Trustee the necessary funds and instruct the Trustee to acquire Shares through on-market transactions at the prevailing market price or at price within a specified price range, so as to satisfy the Award. The Restricted Shares will be held in trust for the Selected Participants (other than US Participants) until the end of each vesting period. When the Selected Participant (other than US Participants) has satisfied all vesting conditions specified by the Board at the time of making the Award and become entitled to the Restricted Shares, the Trustee shall transfer the relevant Restricted Shares to that Selected Participant (other than US Participants).

For US Participants, the Restricted Shares will be satisfied by (i) authorized and unissued Shares, (ii) treasury shares (subject to Applicable Laws), (iii) Shares purchased on the open market, and/or (iv) at the discretion of the Board, ADRs (if any). Restricted Shares awarded to US Participants will not be held or issued through the Trust. Such Restricted Shares shall be issued directly to and held by such US Participant directly and not by the Trustee or in the Trust.

The Company shall comply with the applicable Listing Rules when issuing new Shares and application will be made to the Stock Exchange for granting of the listing of, and permission to deal in, the new Restricted Shares to be issued. The Company shall not issue or allot Shares, nor instruct the Trustee to acquire Shares on the market at the prevailing market price or at price within a specified price range, where such action (as applicable) is prohibited under the Listing Rules, the SFO or other applicable laws from time to time or where such action (as applicable) would render the Company the subject of a mandatory offer under the Codes on Takeovers and Mergers from time to time.

7. Vesting of Restricted Shares

Vesting shall only occur upon satisfaction (or where applicable, waiver by the Board) of the conditions imposed by the Board. The Board or person(s) to which the Board delegated its authority may either (a) direct and procure the Trustee to release from the Trust the Restricted Shares to the Selected Participants (other than US Participants) by transferring the number of Restricted Shares to the Selected Participants (other than US Participants) in such manner as determined by the Board from time to time; or (b) to the extent that, at the determination of the Board or its delegate(s), it is not practicable for the Selected Participants (other than US Participants) to receive the Restricted Shares in Shares solely due to legal or regulatory restrictions with respect to the Selected Participant's (other than US Participants) ability to receive the Restricted Shares in Shares or the Trustee's ability to give effect to any such transfer to the Selected Participant (other than US Participants), the Board or its delegate(s) will direct and procure the Trustee to sell, on the market at the prevailing market price or at price within a specified price range, the number of Restricted Shares so vested in respect of the Selected Participant (other than US Participants) and pay the Selected Participant (other than US Participants) the proceeds in cash arising from such sale based on the Actual Selling Price of such Restricted Shares.

For US Participants, Restricted Shares awarded to US Participants will not be held or issued through the Trust. Such Restricted Shares shall be issued directly to and held by such US Participant directly and not by the Trustee or in the Trust. Each Award will constitute an immediate transfer of the ownership of Restricted Shares to the US Participant in consideration of the performance of services, but subject to the substantial risk of forfeiture and restrictions on transfer.

Subject to the Rules, save as determined otherwise by the Board at its sole discretion, the Selected Participant shall cease immediately to be entitled to all his/her rights and benefits to the Restricted Shares outstanding and unvested in the event that (i) the employment or service contract of the Selected Participant is terminated for whatever reason; (ii) the Selected Participant has been convicted for any criminal offence involving his integrity or honesty; (iii) the Selected Participant has been charged, convicted or held liable for any offence under the relevant securities laws in the PRC, Hong Kong, the United States, or any other applicable laws or regulations in force from time to time; (iv) the Selected Participant has committed any material breach of any contract entered into between the Selected Participant on the one hand and any member of the Group on the other hand; (v) the Selected Participant has become bankrupt or unable to pay his or her debts, or is subject to any bankruptcy or analogous proceedings or has made any arrangement or composition with his or her creditors generally; (vi) the Selected Participant is deceased or becomes mentally incapacitated; (vii) an order for the winding-up of the Company is made or a resolution is passed for the voluntary winding-up of the Company (otherwise than for the purposes of, and followed by, an amalgamation or reconstruction in such circumstances that substantially the whole of the undertaking, assets and liabilities of the Company pass to a successor company); or (viii) the Selected Participant retires by agreement with the Company at any time prior to or on the Vesting Date.

8. Voting Rights

Neither the Selected Participant nor the Trustee may exercise any of the voting rights in respect of any Restricted Shares that have not yet vested. Upon the Restricted Shares being vested and transferred to the Selected Participant, the Selected Participant shall delegate his or her voting rights to Genscript Corporation, as a proxyholder pursuant to a proxy, until such Restricted Shares are transferred by the Selected Participant to a third party.

9. Assignment of Award

Any Award granted under the Scheme are personal to such Selected Participant and cannot be assigned or transferred, except the prior written approval of the Board. Any attempt by each Selected Participant to sell, transfer, charge, mortgage, grant, encumber or create any interest in favor of any third party over the Restricted Shares outstanding and unvested to which he/she is entitled shall be null and void, except in accordance with the Scheme.

10. Alteration of the Scheme

The Scheme may be altered or varied in any respect by a resolution of the Board, provided that such alterations or variations are made in compliance with the memorandum and articles of association of the Company, the Listing Rules and applicable laws.

11. Duration and Termination

The Scheme commences on the Effective Date and remains valid and effective unless and until being terminated upon the expiry of the period of ten years from such date, unless terminated earlier by a resolution of the Board.

Upon termination (whether due to early termination or upon expiry of the Scheme) of the Scheme, no further Restricted Shares shall be granted. Following the lapse, forfeiture or cancellation (as the case may be) of the last outstanding Award made or can be made under the Scheme (whichever is later), the Trustee shall sell all Returned Shares and non-cash income remaining in the Trust, if any, and remit the proceeds of sale of the same together with any Residual Cash accrued in the Trust, after making appropriate deductions in respect of all disposal costs, expenses and other existing and future liabilities to the Company forthwith after the sale.

LISTING RULES IMPLICATION

The Scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules and is a discretionary scheme of the Company. No shareholders' approval is required for the adoption of the Scheme.

DEFINITION

In this announcement, unless the context otherwise requires, the following words and expressions have the meanings ascribed to them below:

Term	Definition
“Actual Selling Price”	the actual price at which the Restricted Shares are sold (net of brokerage, Stock Exchange trading fee, SFC transaction levy and any other applicable costs) on vesting of an Award pursuant to the Scheme or in the case of a vesting when there is an event of change in control or privatisation of the Company pursuant to Rule 18 of the Rules, the consideration receivable under the related scheme or offer
“Adoption Date”	23 August 2021, being the date on which the Scheme is adopted by the Board upon recommendation of the Remuneration Committee
“ADRs”	American Depositary Shares
“Award”	an award granted by the Board to a Selected Participant, which may vest in the form of Restricted Shares or the Actual Selling Price of the Restricted Shares in cash, as the Board may determine in accordance with the terms of the Rules
“Applicable Laws”	means the legal requirements relating to the Scheme and the Awards under applicable provisions of the corporate, securities, tax and other laws, rules, regulations and government orders, and the rules of any applicable stock exchange or national market system, of any jurisdiction applicable to Awards granted to residents therein

“Board”	the board of directors of the Company from time to time
“Company”	GenScript Biotech Cooperation, a company incorporated in Cayman Islands with limited liability, whose shares are listed on the Stock Exchange of Hong Kong Limited
“controlling shareholder”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	directors of the Company or any one of them
“Effective Date”	the execution and effective date of the Trust Deed
“Eligible Participant(s)”	any Director or employee of the Company or any of its subsidiaries
“Genscript Corporation”	Genscript Corporation, a company incorporated on 3 July 2002, under the laws of the State of Delaware of the United States, which is one of the controlling shareholders of the Company
“Group”	the Company and its subsidiaries from time to time
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China (for the purpose of this announcement, excluding Hong Kong, the Macao Special Administrative Region of the PRC and Taiwan)
“Related Income”	all income derived from any Share (including, but not limited to, dividends and other cash distributions, any bonus Shares and scrip Shares received in respect of the Share) held upon the Trust. For the avoidance of doubt, nil paid rights, bonus warrants, non-cash and non-scrip distributions are excluded
“Residual Cash”	cash remaining in the Trust Fund and sale proceeds (including the cash proceeds of sale of non-cash and non-scrip distributions declared and distributed by the Company in respect of any Shares held upon the Trust), other than Related Income
“Restricted Share(s)”	any Share that may be offered by the Company to any Selected Participant pursuant to the Scheme
“Returned Shares”	such Restricted Shares that are not vested and/or are forfeited in accordance with the terms of the Scheme, or such Shares being deemed to be Returned Shares under the Rules

“Rules”	the rules of the Scheme adopted by the Board on the Adoption Date
“Scheme” or “Restricted Share Award Scheme”	the scheme constituted by the Rules as amended from time to time
“Selected Participant(s)”	any Eligible Participant(s) selected by the Board in accordance with the terms of the Scheme
“SFO”	the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), as amended from time to time
“Shares”	shares of US\$0.001 each in the share capital of the Company (or of such other nominal amount as may result from a sub-division, consolidation, reclassification or reconstruction of such share capital from time to time) that are listed on the Stock Exchange of Hong Kong Limited
“Trust”	the trusts constituted under the Trust Deed
“Trust Deed”	a trust deed to be entered into between the Company and the Trustee (as restated, supplemented and amended from time to time) in respect of the appointment of the Trustee for the administration of the Scheme
“Trust Fund”	(a) any Shares acquired by the Trustee for the purpose of the Trust out of cash paid to the Trustee by way of settlement or otherwise contributed by the Company by way of allotment of new shares; (b) all Residual Cash, Related Income and Related Distributions of, and such other scrip income (including but not limited to bonus Shares and scrip dividends declared by the Company) derived from, the Shares held by the Trust; and (c) all other properties from time to time representing (a) and (b) above
“Trustee”	the trustee corporation or trustee corporations (which is/are independent of and not connected with the Company) to be appointed by the Company for the administration of the Scheme or any additional or replacement trustee(s)
“United States”	the United States of America
“US Participant”	means any Selected Participant who is a United States resident and/or is subject to United States tax pursuant to the Code

“Vesting Date”	the date on which the Restricted Shares is vested by a Selected Participant
“2019 Scheme”	the restricted share award scheme of the Company adopted on 22 March 2019
“%”	per cent.

By order of the Board
GenScript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 24 August 2021

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purpose only*